QUANTITATIVE ASPECTS OF DRUG ACTION

Slides:



Advertisements
Similar presentations
Introduction to Pharmacology
Advertisements

LAKSHMAN KARALLIEDDE OCTOBER 2011
DRUG-RECEPTOR INTERACTIONS
Bruce Wainman, PhD. Drugs and Marketing Drugs are often marketed as the most potent, the most efficacious, the most effective and the best tolerated The.
QUANTITATIVE ASPECTS OF DRUG ACTIONS DR. SHABANA ALI.
QUANTITATIVE ASPECTS OF DRUG ACTION ilo s By the end of this lecture you will be able to :  Recognize different dose response curves  Classify different.
Pharmacology-1 PHL 313 Fifth Lecture By Abdelkader Ashour, Ph.D. Phone:
Drug ? RESPONSE altering their biochemical &/or biophysical activity  Depress  Activate  Replace  Irritate  Destroy PHARMACODYNAMICS  Absorb 
Dose-Response Relationships Lesson 6. Dose & Drug Effects n Pharmacodynamics l what the drug does to the body n Effects of drug depends on dose n In general...
Pharmacology Introduction
PHL 211 Pharmacology Fifth Lecture By Abdelkader Ashour, Ph.D. Phone:
Pharmacodynamics Chapter 2. Concentration/Response Relationship Can meas drug/ receptor binding directly –Ex: Radioimmunoassay Ex: radioactive drug binding.
Pharmacology-1 PHL 313 Fourth Lecture By Abdelkader Ashour, Ph.D. Phone:
OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.
Drug-Receptor Interactions Pharmacodynamics
Principles of Pharmacology: Pharmacodynamics

Principles of Pharmacology: Pharmacodynamics
PHC 222 Part(I) Dr. Huda Al Salem Lecture (7). Factors that affect the efficacy 2- Concentration-Response Curves: Agonist Antagonist Partial agonist Desensetization.
Types of antagonists. Antagonists, Overview  Definition “An antagonist is a substance that does not provoke a biological response itself, but blocks.
BASIC PHARMACOLOGY 2 SAMUEL AGUAZIM(MD).
RESPONSE altering their biochemical &/or biophysical activity  Depress  Activate  Replace  Irritate  Destroy PHARMACODYNAMICS  Absorb  Distribute.
HuBio 543 September 6, 2007 Frank F. Vincenzi
How drugs Act :General principles Lecture 2
Year One Pharmacodynamics
PHARMACOLOGY INTRODUCTION
PHARMACODYNAMICS M.T. Piascik PHA 824 November 11, 2008.
At the end of this lecture, the students will be able to: 1.Define receptors 2.Define agonists 3.List types of agonists 4. Define antagonists 5. List.
Dr. Laila M. Matalqah Ph.D. Pharmacology Pharmacodynamics 2 General Pharmacology M212.
415 PHT Plasma Level – Time Curve
Clinical Pharmacokinetics. Time course Duration Onset Absorptive phase Elimination phase.
Biological Evaluation Lecture - 4 Principles and Importance of BA’s Joseph O. Oweta B. Pharm (MUST)
Pharmacodynamics. Pharmacodynamics  The study of the biochemical and physiologic effects of drugs and the molecular mechanisms by which those effects.
DRUG RECEPTORS AND PHARMACODYNAMICS
QUANTITATIVE ASPECTS OF DRUG ACTION
Section 1, Lecture 8 Receptor Classification according to: -which drugs they interact with (  -adrenergic –binds norepinphine with high affinity.
INTRODUCTION Lecture 3. Pharmacodynamics Receptor: macromolecule that interacts with a drug and initiates the chain of biochemical events leading to the.
Dept. Pharmacology & Therapeutic Universitas Sumatera Utara
Pharmacodynamics What the drug does to the body?
To record DRC of Acetylcholine using rat ileum
Pharmacodynamics Collected and Prepared By S.Bohlooli, PhD.
QUANTITATIVE ASPECTS OF DRUG ACTION ilo s By the end of this lecture you will be able to :  Recognize different dose response curves  Classify different.
Pharmacodynamics. * The study of the biochemical and physiologic effects of drugs and the molecular mechanisms by which those effects are produced * The.
OMICS International OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community.
5 Pharmacodynamics.
Pharmacodynamics 3.
Pharmacology-1 PHL 351 Abdelkader Ashour, Ph.D..
DRUG ANTAGONISM DR. SHABANA ALI.
MBBS-BDS LECTURE NOTES
Brief Review of Dr. Swanson’s and Dr. Prakriya’s material
5 Pharmacodynamics.
Drug-Receptor Interactions
INTRODUCTION to Pharmacology
Pharmacodynamics 2.
Principles of pharmacodynamics
Pharmacology UG-Course
Drug-Receptor Interactions
Pharmacodynamic Dr. Hashem Mansour.
Introduction to Pharmacology
By Amany Helmy Hasanin Assistant Professor of Clinical Pharmacology
Efficacy, Potency and Safety of Drugs
Drug ½ life time it takes plasma concentration or amount of drug in body to be reduced by 50% Provides a good indication of the time necessary to reach.
ANTAGONISTS Antagonists are substances which block the action of agonists There are a number of types COMPETITIVE NON-COMPETITIVE PARTIAL AGONISTS PHYSIOLOGICAL.
Drug-Receptor Interaction
Introduction to Pharmacology
Drug-Receptor Interactions and Pharmacodynamics (cont.)
Non-competitive antagonism
Drug- Receptor Interaction
Drug-Receptor Interaction
Full agonists The “agonists” referred to so far are FULL AGONISTS
Presentation transcript:

QUANTITATIVE ASPECTS OF DRUG ACTION ilos By the end of this lecture you will be able to : Determine quantitative aspects of drug receptor binding Recognize different dose response curves Distinguish the therapeutic utility of each of these curves Classify different types of antagonism QUANTITATIVE ASPECTS OF DRUG ACTION

QUANTIFY ASPECTS OF DRUG ACTION Bind Occupy Initiate Activate RESPONSE[R] + DR* Relate concentration [C] of D used (x- axis) to the binding capacity at receptors (y-axis) Relate concentration [C] of D used (x- axis) to the R produced (y-axis) Concentration-Binding Curve Dose Response Curve AFFINITY EFFICACY POTENCY

Concentration-Binding Curve Occupy Initiate Activate association rate constant k1 D + R D R DR* RESPONSE[R] k2 dissociation rate constant The relationship between drug binding & drug concentration is expressed mathematically by the following equation B = ----------- Bmax xC C+ KD50

? ? ? Concentration-Binding Curve (Bmax): Total density of receptors in the tissue KD KD (kD ) = [C] of D required to occupy 50% of receptors at equilibrium ? Concentration-Binding curves are used to determine: The binding capacity (Bmax) → total density of receptors in the tissues. The affinity of D for receptor The higher the affinity of D for receptor the lower is the KD i.e. inverse relation ? ?

How does response vary with C? BP, HR, FBG, Cholesterol,… DOSE RESPONSE CURVE How does response vary with C? A continuous response BP, HR, FBG, Cholesterol,… GRADED DOSE RESPONSE CURVE An all-or-non response prevention of convulsion, arrhythmias or death….. Relate C to % of patients eliciting the : * specified therapeutic response * adverse response * lethal outcome QUANTAL DOSE RESPONSE CURVE How the therapeutic window of a drug is defined ?

DOSE RESPONSE CURVE GRADED DOSE RESPONSE CURVE QUANTAL DOSE RESPONSE CURVE

BP, HR, FBG, Cholesterol,… GRADED DOSE RESPONSE CURVE A continuous response BP, HR, FBG, Cholesterol,…

GRADED DOSE RESPONSE CURVE Max effect = Emax Effect when all the receptors are occupied by D % of Maximal Effect [C] 20 40 60 80 100 200 400 600 800 20 40 60 80 100 1 10 1000 % of Maximal Effect [C] EC50 As C ↑ response increment ↓ E= ----------- Emax xC C+ EC50 EC50 Graded dose-response curves are used to determine: The max efficacy (Emax) → highest limit of dose-response relationship on response axis. The potency = The concentration of drug required to produce a specified response The smaller the EC50 , the greater the potency of the agonist, i.e the lower C needed to elicit the maximum biological response. 3. Compare the relative potency and efficacy of drugs that produce the same effect. C that gives the half-maximal effect

GRADED DOSE RESPONSE CURVE EFFICACY A > efficacy than B B Partial Agonist POTENCY A > potent B

X & Z > efficacy than Y < efficacious than Z GRADED DOSE RESPONSE CURVE X & Z are equal efficacy X & Z > efficacy than Y Y > potent but < efficacious than Z X > potent than Y & Z Y> potent than Z

DOSE RESPONSE CURVE GRADED DOSE RESPONSE CURVE QUANTAL DOSE RESPONSE CURVE

Dose-frequency relationship QANTAL DOSE RESPONSE CURVE All-non responses * specified therap. response * adverse response * lethal outcome % subjects responding Dose-frequency relationship

Predict the safety profile QANTAL DOSE RESPONSE CURVE: used to determine 100 Lethal Effect 80 Toxic Effect Therapeutic Effect 60 % subjects responding 40 20 [Dose] 1 10 100 1000 ED50 TD50 LD50 Median Effective Dose 50% of individuals exhibit the specified therapeutic response Median toxic dose Median lethal dose Therapeutic Index TD50 ED50 The relation between dose to induce a desired effect versus that producing the unwanted effect. When low → the drug has a narrow margin of safety digoxin When high → the drug has a safe profile diazepam

ANTAGONISM It is the diminution or the complete abolishment of the effect of one drug in the presence of another. Types Chemical Physiological Pharmacokinetic Receptor Blockade Competitive Non-Competitive The antagonist effectively reduces the concentration of the active drug at the site of action Two drugs react chemically resulting in loss of activity of active drug Dimercaprol reduces heavy metal toxicity [ lead, ….] Phenobarbitone induces an accelerated hepatic metabolism warfarine Two drugs possess opposing actions in the body, so tend to cancel each other’s effect Omeprozole & histamine

ANTAGONISM Non-Competitive Receptor Blockade Reversible Competitive Antagonist block at some point the chain of events that ignite the response of agonist Agonist and Antagonist can be bound simultaneously Receptor Blockade Competitive Reversible Antagonist prevents binding of agonist to the receptor at the same binding site ( = competes with it at same occupancy site ) Agonist and Antagonist compete ( only one is bound) Irreversible

COMPETATIVE ANTAGONISM Irreversible Reversible Antagonist readily dissociate from binding site of agonist to the receptor Antagonism can be overcome by increasing concentration of agonist = Surmountable Atropine vs Ach Antagonist form stable, permanent / near permanent chemical bond with receptor. Inactivation lasts for duration of receptor turnover or its de- novo synthesis → explains its longevity of action Phenoxybenzamine & Noradrenaline

Competitive Antagonism Reversible Parellel shift to the right, without any change in slope or maximum Irreversible No parellel shift but both a decrease in slope and a reduced maximum are obtained.

Competitive vs Noncompetative Antagonism Antagonism can be overcomed by increasing concentration of agonist = SURMOUNTABLE % of Maximal Effect Agonist + reversible competitive antagonist 20 40 60 80 100 Agonist Agonist + irreversible competitive antagonist Agonist + non-competitive antagonist Depression of maximal response +/- rightward shifts ( if some R are spare ) Verapamil vs noradrenaline [C] 1 10 100 1000 Antagonism cannot be overcome by increasing concentration of agonist = NON-SURMOUNTABLE

QUANTITATIVE ASPECTS OF DRUG ACTION L U C K By the end of this lecture you ARE able to : Determine quantitative aspects of drug receptor binding Recognize different dose response curves Distinguish the therapeutic utility of each of these curves Classify different types of antagonism